1. Home
  2. VNDA vs GSRT Comparison

VNDA vs GSRT Comparison

Compare VNDA & GSRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNDA
  • GSRT
  • Stock Information
  • Founded
  • VNDA 2002
  • GSRT 2023
  • Country
  • VNDA United States
  • GSRT United States
  • Employees
  • VNDA N/A
  • GSRT N/A
  • Industry
  • VNDA Biotechnology: Pharmaceutical Preparations
  • GSRT
  • Sector
  • VNDA Health Care
  • GSRT
  • Exchange
  • VNDA Nasdaq
  • GSRT Nasdaq
  • Market Cap
  • VNDA 282.8M
  • GSRT 292.6M
  • IPO Year
  • VNDA 2006
  • GSRT 2024
  • Fundamental
  • Price
  • VNDA $4.98
  • GSRT $10.00
  • Analyst Decision
  • VNDA Strong Buy
  • GSRT
  • Analyst Count
  • VNDA 2
  • GSRT 0
  • Target Price
  • VNDA $16.50
  • GSRT N/A
  • AVG Volume (30 Days)
  • VNDA 751.6K
  • GSRT 3.4K
  • Earning Date
  • VNDA 05-07-2025
  • GSRT 01-01-0001
  • Dividend Yield
  • VNDA N/A
  • GSRT N/A
  • EPS Growth
  • VNDA N/A
  • GSRT N/A
  • EPS
  • VNDA N/A
  • GSRT N/A
  • Revenue
  • VNDA $198,772,000.00
  • GSRT N/A
  • Revenue This Year
  • VNDA $14.36
  • GSRT N/A
  • Revenue Next Year
  • VNDA $44.53
  • GSRT N/A
  • P/E Ratio
  • VNDA N/A
  • GSRT N/A
  • Revenue Growth
  • VNDA 3.18
  • GSRT N/A
  • 52 Week Low
  • VNDA $3.71
  • GSRT $9.97
  • 52 Week High
  • VNDA $6.75
  • GSRT $10.23
  • Technical
  • Relative Strength Index (RSI)
  • VNDA 58.23
  • GSRT N/A
  • Support Level
  • VNDA $4.84
  • GSRT N/A
  • Resistance Level
  • VNDA $5.10
  • GSRT N/A
  • Average True Range (ATR)
  • VNDA 0.24
  • GSRT 0.00
  • MACD
  • VNDA 0.02
  • GSRT 0.00
  • Stochastic Oscillator
  • VNDA 76.40
  • GSRT 0.00

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

About GSRT GSR III Acquisition Corp. Ordinary Shares

GSR III Acquisition Corp is a blank check company.

Share on Social Networks: